



ABOUT ARRAY BIOPHARMA



Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: encorafenib, binimetinib, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

IN THE NEWS



COLUMBUS Phase 3: Encorafenib and binimetinib mOS 33.6 months

BEACON CRC Safety Lead-in at 2018 ASCO GI: Triple combination mPFS 8.0 months; 48% ORR, including 3 CRs

BY THE NUMBERS



NASDAQ	ARRY
Market Capitalization	>\$3B
Staff	250
Cash (12/31/17)	\$420.3M
Headquarters	Boulder, CO

www.arraybiopharma.com
 Info@arraybiopharma.com
 303.381.6600
 3200 Walnut Street
 Boulder, Colorado 80301

Path to Commercialization & Upcoming Catalysts

Significant Pipeline Milestones Achieved...

... Important Value-Drivers

NEAR-TERM COMMERCIAL / BRAF-MUTANT MELANOMA 	NDAs & MAAs for BRAFm melanoma under regulatory review <ul style="list-style-type: none"> Secondary endpoint: mOS 33.6 months Phase 3 met primary endpoint: mPFS 14.9 months 	Global regulatory reviews FDA PDUFA June 30, 2018; FDA not currently planning to hold an ODAC
PHASE 3 / BRAF-MUTANT CRC 	Promising activity in safety lead-in reported at ASCO GI 2018 <ul style="list-style-type: none"> Triple combination well-tolerated 8.0 months mPFS; 48% confirmed ORR, including 3 CRs 	Randomized portion of trial actively enrolling
I/O COLLABORATIONS 	BMS collaboration Binimetinib + nivolumab +/- ipilimumab in patients with RASm MSS CRC	Trial active
	Merck-sponsored collaboration Binimetinib + pembrolizumab +/- FOLFOX or FOLFIRI in patients with MSS CRC	Trial active
	Pfizer-sponsored collaboration Binimetinib + avelumab +/- talazoparib in patients with cancer	Trial to begin 3Q2018

COST SHARING

Novartis reimbursement totaled \$88.5M past 12 reported months
 BEACON CRC co-funding: Pierre Fabre (40%), Ono Pharmaceuticals (milestone payments), Merck KGaA (Erbix supply)

Strategy

We are building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer. We intend to accomplish this through the following strategies:



Invent targeted small molecule drugs that are either first-in-class or second generation drugs that have little or no competition, or demonstrate a competitive advantage over drugs currently on the market or in clinical development.



Selectively develop and commercialize our drugs to maximize their overall value. As our first drug nears approval, we are building a U.S.-based, therapeutically focused sales force to commercialize or co-promote drugs we wholly own or for which we retain development rights in certain geographic areas.



Implement a partnering strategy in which we retain U.S. commercial and/or co-promotion rights for drugs that can be distributed through a therapeutically specialized sales force and partner select early-stage programs for continued research and development to receive research funding plus significant milestone payments and royalties.

Partnerships

